Journal of Neuroinflammation (May 2020)

PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study

  • Stal Shrestha,
  • Min-Jeong Kim,
  • Mark Eldridge,
  • Michael L. Lehmann,
  • Michael Frankland,
  • Jeih-San Liow,
  • Zu-Xi Yu,
  • Michelle Cortes-Salva,
  • Sanjay Telu,
  • Ioline D. Henter,
  • Evan Gallagher,
  • Jae-Hoon Lee,
  • J. Megan Fredericks,
  • Chelsie Poffenberger,
  • George Tye,
  • Yanira Ruiz-Perdomo,
  • Fernanda Juarez Anaya,
  • Jose A. Montero Santamaria,
  • Robert L. Gladding,
  • Sami S. Zoghbi,
  • Masahiro Fujita,
  • James D. Katz,
  • Victor W. Pike,
  • Robert B. Innis

DOI
https://doi.org/10.1186/s12974-020-01804-6
Journal volume & issue
Vol. 17, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Background Cyclooxygenase-2 (COX-2), which is rapidly upregulated by inflammation, is a key enzyme catalyzing the rate-limiting step in the synthesis of several inflammatory prostanoids. Successful positron emission tomography (PET) radioligand imaging of COX-2 in vivo could be a potentially powerful tool for assessing inflammatory response in the brain and periphery. To date, however, the development of PET radioligands for COX-2 has had limited success. Methods The novel PET tracer [11C]MC1 was used to examine COX-2 expression [1] in the brains of four rhesus macaques at baseline and after injection of the inflammogen lipopolysaccharide (LPS) into the right putamen, and [2] in the joints of two human participants with rheumatoid arthritis and two healthy individuals. In the primate study, two monkeys had one LPS injection, and two monkeys had a second injection 33 and 44 days, respectively, after the first LPS injection. As a comparator, COX-1 expression was measured using [11C]PS13. Results COX-2 binding, expressed as the ratio of specific to nondisplaceable uptake (BP ND) of [11C]MC1, increased on day 1 post-LPS injection; no such increase in COX-1 expression, measured using [11C]PS13, was observed. The day after the second LPS injection, a brain lesion (~ 0.5 cm in diameter) with high COX-2 density and high BP ND (1.8) was observed. Postmortem brain analysis at the gene transcript or protein level confirmed in vivo PET results. An incidental finding in an unrelated monkey found a line of COX-2 positivity along an incision in skull muscle, demonstrating that [11C]MC1 can localize inflammation peripheral to the brain. In patients with rheumatoid arthritis, [11C]MC1 successfully imaged upregulated COX-2 in the arthritic hand and shoulder and apparently in the brain. Uptake was blocked by celecoxib, a COX-2 preferential inhibitor. Conclusions Taken together, these results indicate that [11C]MC1 can image and quantify COX-2 upregulation in both monkey brain after LPS-induced neuroinflammation and in human peripheral tissue with inflammation. Trial registration ClinicalTrials.gov NCT03912428. Registered April 11, 2019.

Keywords